JPRN-C000000064
Completed
Phase 2
Phase 2 Study of Applying Pediatric Regimens to Younger Adult Patients with BCR-ABL-Negative Acute Lymphoblastic Leukemia (JALSG ALL202-U) - Phase 2 Study of Applying Pediatric Regimens to Younger Adult Patients with ALL (JALSG ALL202-U)
ConditionsAcute lymphoblastic leukemia
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Acute lymphoblastic leukemia
- Sponsor
- Japan Adult Leukemia Study Group
- Enrollment
- 120
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1\) Uncontrolled active infection (2\) Another severe and/or life\-threatening disease (3\) Positive for HIV antibody and/or HBs antigen tests (4\) Another primary malignancy which is clinically active and/or requires medical interventions (5\) Pregnant and/or lactating woman (6\) Past history of renal failure
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Paediatric onset study to assess the efficacy of insulin pump therapy using the MiniMed Paradigm® REAL-Time system during the first year of diabetes in children and adolescents with type 1 diabetesISRCTN05450731Hannover Childrens Hospital (Hannoversche Kinderheilanstalt) (Germany)160
Completed
Phase 2
A Multicentre trial for the treatment of adolescents aged 15 years and above, and young adults aged up to 40 years, with newly diagnosed Acute Lymphoblastic Leukaemia (ALL)ntreated ALL aged 15 to 40 yearsUntreated ALL aged 15 to 40 yearsCancer - Leukaemia - Acute leukaemiaACTRN12611000814976Australasian Leukaemia and Lymphoma Group86
Not yet recruiting
Phase 3
Assessment of praziquantel medication for children living in areas where schistosomiasis is common in Bahia and SergipeRBR-86kcy37Instituto Gonçalo Moniz (IGM) - Fundação Oswaldo Cruz (Fiocruz-BA)
Completed
Phase 2
A Multi-Center Phase II Study in Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL)Acute promyelocytic leukemiaJPRN-UMIN000015348Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)32
Active, not recruiting
Phase 1
A PAEDIATRIC PHASE I/II STUDY OF INTERMITTENT DOSING OF THE MEK-1 INHIBITOR SELUMETINIB IN CHILDREN WITH NEUROFIBROMATOSIS TYPE-1 AND INOPERABLE PLEXIFORM NEUROFIBROMA AND/OR PROGRESSIVE OPTIC PATHWAY GLIOMANeurofibromatosis type 1 associated plexiform neurofibromas Neurofibromatosis type 1 associated progressive or relapsed optic pathway gliomaMedDRA version: 20.0 Level: LLT Classification code 10029270 Term: Neurofibromatosis, type 1 (von Recklinghausen's disease) System Organ Class: 100000004850MedDRA version: 20.0 Level: LLT Classification code 10065866 Term: Plexiform neurofibroma System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10030935 Term: Optic nerve glioma System Organ Class: 100000004864Therapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2017-002635-41-GBGreat Ormond Street Hospital38